Interplay between Candida albicans and the antimicrobial peptide armory

Eukaryotic Cell

Volumn 13, Issue 8, 2014, Pages 950-957

  Swidergall, Marc ^a   Ernst, Joachim F ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANDIDA ALBICANS;

ANTIFUNGAL AGENT; ANTIMICROBIAL CATIONIC PEPTIDE;

ANIMAL; ANTIFUNGAL RESISTANCE; CANDIDA ALBICANS; CANDIDIASIS; DRUG EFFECTS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; MICROBIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE;

EID: 84907478489     PISSN: 15359778     EISSN: None     Source Type: Journal    
DOI: 10.1128/EC.00093-14     Document Type: Review

References (90)

1. Cheng SC, Joosten LA, Kullberg BJ, Netea MG. 2012. Interplay between Candida albicans and the mammalian innate host defense. Infect. Immun. 80:1304-1313. http://dx.doi.org/10.1128/IAI.06146-11.
2. Hube B. 2004. From commensal to pathogen: stage- and tissue-specific gene expression of Candida albicans. Curr. Opin. Microbiol. 7:336-341. http://dx.doi.org/10.1016/j.mib.2004.06.003.
3. Vandamme D, Landuyt B, Luyten W, Schoofs L. 2012. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell. Immunol. 280:22-35. http://dx.doi.org/10.1016/j.cellimm.2012.11.009.
4. Lehrer RI, Ganz T. 1999. Antimicrobial peptides in mammalian and insect host defence. Curr. Opin. Immunol. 11:23-27. http://dx.doi.org/10. 1016/S0952-7915(99)80005-3.
5. Peschel A, Sahl HG. 2006. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat. Rev. Microbiol. 4:529-536. http://dx.doi.org/10.1038/nrmicro1441.
6. van't Hof W, Veerman EC, Helmerhorst EJ, Amerongen AV. 2001. Antimicrobial peptides: properties and applicability. Biol. Chem. 382: 597-619.
7. Vylkova S, Sun JN, Edgerton M. 2007. The role of released ATP in killing Candida albicans and other extracellular microbial pathogens by cationic peptides. Purinergic Signal 3:91-97. http://dx.doi.org/10.1007/s11302 -006-9040-0.
8. Steinstraesser L, Kraneburg U, Jacobsen F, Al-Benna S. 2011. Host defense peptides and their antimicrobial-immunomodulatory duality. Immunobiology 216:322-333. http://dx.doi.org/10.1016/j.imbio.2010.07. 003.
9. den Hertog AL, van Marle J, van Veen HA, Van't Hof W, Bolscher JG, Veerman EC, Nieuw Amerongen AV. 2005. Candidacidal effects of two antimicrobial peptides: histatin 5 causes small membrane defects, but LL-37 causes massive disruption of the cell membrane. Biochem. J. 388: 689-695. http://dx.doi.org/10.1042/BJ20042099.
10. Chang HT, Tsai PW, Huang HH, Liu YS, Chien TS, Lan CY. 2012. LL37 and hBD-3 elevate the beta-1,3-exoglucanase activity of Candida albicans Xog1p, resulting in reduced fungal adhesion to plastic. Biochem. J. 441: 963-970. http://dx.doi.org/10.1042/BJ20111454.
11. Tsai PW, Yang CY, Chang HT, Lan CY. 2011. Human antimicrobial peptide LL-37 inhibits adhesion of Candida albicans by interacting with yeast cell-wall carbohydrates. PLoS One 6:e17755. http://dx.doi.org/10. 1371/journal.pone.0017755.
12. Murakami M, Lopez-Garcia B, Braff M, Dorschner RA, Gallo RL. 2004. Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J. Immunol. 172:3070-3077. http://dx.doi. org/10.4049/jimmunol.172.5.3070.
13. den Hertog AL, Van Marle J, Veerman ECI, Valentijn-Benz M, Nazmi K, Kalay H, Grün CH, Van't Hof W, Bolscher JGM, Amerongen AVN. 2006. The human cathelicidin peptide LL-37 and truncated variants induce segregation of lipids and proteins in the plasma membrane of Candida albicans. Biol. Chem. 387:1495-1502.
14. Komatsu T, Salih E, Helmerhorst EJ, Offner GD, Oppenheim FG. 2011. Influence of histatin 5 on Candida albicans mitochondrial protein expression assessed by quantitative mass spectrometry. J. Proteome Res. 10:646- 655. http://dx.doi.org/10.1021/pr100861k.
15. Sun JN, Li W, Jang WS, Nayyar N, Sutton MD, Edgerton M. 2008. Uptake of the antifungal cationic peptide histatin 5 by Candida albicans Ssa2p requires binding to non-conventional sites within the ATPase domain. Mol. Microbiol. 70:1246-1260. http://dx.doi.org/10.1111/j.1365 -2958.2008.06480.x.
16. Kumar R, Chadha S, Saraswat D, Bajwa JS, Li RA, Conti HR, Edgerton M. 2011. Histatin 5 uptake by Candida albicans utilizes polyamine transporters Dur3 and Dur31 proteins. J. Biol. Chem. 286:43748-43758. http: //dx.doi.org/10.1074/jbc.M111.311175.
17. Mayer FL, Wilson D, Jacobsen ID, Miramon P, Grosse K, Hube B. 2012. The novel Candida albicans transporter Dur31 is a multi-stage pathogenicity factor. PLoS Pathog. 8:e1002592. http://dx.doi.org/10.1371 /journal.ppat.1002592.
18. Helmerhorst EJ, Troxler RF, Oppenheim FG. 2001. The human salivary peptide histatin 5 exerts its antifungal activity through the formation of reactive oxygen species. Proc. Natl. Acad. Sci. U. S. A. 98:14637-14642. http://dx.doi.org/10.1073/pnas.141366998.
19. Koshlukova SE, Araujo MW, Baev D, Edgerton M. 2000. Released ATP is an extracellular cytotoxic mediator in salivary histatin 5-induced killing of Candida albicans. Infect. Immun. 68:6848-6856. http://dx.doi.org/10. 1128/IAI.68.12.6848-6856.2000.
20. Puri S, Edgerton M. 2014. How does it kill?: understanding the candidacidal mechanism of salivary histatin 5. Eukaryot. Cell 13:958-964.
21. Edgerton M, Koshlukova SE, Araujo MW, Patel RC, Dong J, Bruenn JA. 2000. Salivary histatin 5 and human neutrophil defensin 1 kill Candida albicans via shared pathways. Antimicrob. Agents Chemother. 44:3310- 3316. http://dx.doi.org/10.1128/AAC.44.12.3310-3316.2000.
22. Krishnakumari V, Rangaraj N, Nagaraj R. 2009. Antifungal activities of human beta-defensins HBD-1 to HBD-3 and their C-terminal analogs Phd1 to Phd3. Antimicrob. Agents Chemother. 53:256-260. http://dx.doi. org/10.1128/AAC.00470-08.
23. Situ H, Wei G, Smith CJ, Mashhoon S, Bobek LA. 2003. Human salivary MUC7 mucin peptides: effect of size, charge and cysteine residues on antifungal activity. Biochem. J. 375:175-182. http://dx.doi.org/10.1042 /BJ20030779.
24. Harder J, Schroder JM. 2002. RNase 7, a novel innate immune defense antimicrobial protein of healthy human skin. J. Biol. Chem. 277:46779- 46784. http://dx.doi.org/10.1074/jbc.M207587200.
25. Abtin A, Eckhart L, Mildner M, Ghannadan M, Harder J, Schroder JM, Tschachler E. 2009. Degradation by stratum corneum proteases prevents endogenous RNase inhibitor from blocking antimicrobial activities of RNase 5 and RNase 7. J. Investig. Dermatol. 129:2193-2201. http://dx.doi. org/10.1038/jid.2009.35.
26. Lupetti A, Paulusma-Annema A, Welling MM, Senesi S, van Dissel JT, Nibbering PH. 2000. Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob. Agents Chemother. 44: 3257-3263. http://dx.doi.org/10.1128/AAC.44.12.3257-3263.2000.
27. Bolscher J, Nazmi K, van Marle J, van't Hof W, Veerman E. 2012. Chimerization of lactoferricin and lactoferrampin peptides strongly potentiates the killing activity against Candida albicans. Biochem. Cell Biol. 90:378-388. http://dx.doi.org/10.1139/o11-085.
28. Wagener J, Schneider JJ, Baxmann S, Kalbacher H, Borelli C, Nuding S, Kuchler R, Wehkamp J, Kaeser MD, Mailander-Sanchez D, Braunsdorf C, Hube B, Schild L, Forssmann WG, Korting HC, Liepke C, Schaller M. 2013. A peptide derived from the highly conserved protein GAPDH is involved in tissue protection by different antifungal strategies and epithelial immunomodulation. J. Investig. Dermatol. 133:144-153. http://dx. doi.org/10.1038/jid.2012.254.
29. Mehra T, Koberle M, Braunsdorf C, Mailander-Sanchez D, Borelli C, Schaller M. 2012. Alternative approaches to antifungal therapies. Exp. Dermatol. 21:778-782.
30. Hassan M, Kjos M, Nes IF, Diep DB, Lotfipour F. 2012. Natural antimicrobial peptides from bacteria: characteristics and potential applications to fight against antibiotic resistance. J. Appl. Microbiol. 113:723- 736. http://dx.doi.org/10.1111/j.1365-2672.2012.05338.x.
31. Selsted ME, Ouellette AJ. 2005. Mammalian defensins in the antimicrobial immune response. Nat. Immunol. 6:551-557. http://dx.doi.org/10. 1038/ni1206.
32. Li M, Chen Q, Shen Y, Liu W. 2009. Candida albicans phospholipomannan triggers inflammatory responses of human keratinocytes through Toll-like receptor 2. Exp. Dermatol. 18:603-610. http://dx.doi.org/10. 1111/j.1600-0625.2008.00832.x.
33. Moyes DL, Runglall M, Murciano C, Shen C, Nayar D, Thavaraj S, Kohli A, Islam A, Mora-Montes H, Challacombe SJ, Naglik JR. 2010. A biphasic innate immune MAPK response discriminates between the yeast and hyphal forms of Candida albicans in epithelial cells. Cell Host Microbe 8:225-235. http://dx.doi.org/10.1016/j.chom.2010.08.002.
34. Eyerich S, Wagener J, Wenzel V, Scarponi C, Pennino D, Albanesi C, Schaller M, Behrendt H, Ring J, Schmidt-Weber CB, Cavani A, Mempel M, Traidl-Hoffmann C, Eyerich K. 2011. IL-22 and TNF-alpha represent a key cytokine combination for epidermal integrity during infection with Candida albicans. Eur. J. Immunol. 41:1894-1901. http://dx.doi.org/10. 1002/eji.201041197.
35. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. 2004. IL-22 increases the innate immunity of tissues. Immunity 21:241-254. http://dx.doi.org/10.1016/j.immuni.2004.07.007.
36. Kao CY, Chen Y, Thai P, Wachi S, Huang F, Kim C, Harper RW, Wu R. 2004. IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways. J. Immunol. 173:3482-3491. http://dx.doi.org/10.4049/jimmunol.173.5.3482.
37. Rehaume LM, Jouault T, Chamaillard M. 2010. Lessons from the inflammasome: a molecular sentry linking Candida and Crohn's disease. Trends Immunol. 31:171-175. http://dx.doi.org/10.1016/j.it.2010.01.007.
38. Lu Q, Jayatilake JA, Samaranayake LP, Jin L. 2006. Hyphal invasion of Candida albicans inhibits the expression of human beta-defensins in experimental oral candidiasis. J. Investig. Dermatol. 126:2049-2056. http: //dx.doi.org/10.1038/sj.jid.5700346.
39. Weindl G, Naglik JR, Kaesler S, Biedermann T, Hube B, Korting HC, Schaller M. 2007. Human epithelial cells establish direct antifungal defense through TLR4-mediated signaling. J. Clin. Invest. 117:3664-3672.
40. Kawai K, Shimura H, Minagawa M, Ito A, Tomiyama K, Ito M. 2002. Expression of functional Toll-like receptor 2 on human epidermal keratinocytes. J. Dermatol. Sci. 30:185-194. http://dx.doi.org/10.1016/S0923 -1811(02)00105-6.
41. Pahl R, Brunke G, Steubesand N, Schubert S, Bottner M, Wedel T, Jurgensen C, Hampe J, Schafer H, Zeissig S, Schreiber S, Rosenstiel P, Reiss K, Arlt A. 2011. IL-1beta and ADAM17 are central regulators of beta-defensin expression in Candida esophagitis. Am. J. Physiol. Gastrointest. Liver Physiol. 300:G547-G553. http://dx.doi.org/10.1152/ajpgi. 00251.2010.
42. Wuerth K, Hancock RE. 2011. New insights into cathelicidin modulation of adaptive immunity. Eur. J. Immunol. 41:2817-2819. http://dx.doi.org /10.1002/eji.201142055.
43. Campbell Y, Fantacone ML, Gombart AF. 2012. Regulation of antimicrobial peptide gene expression by nutrients and by-products of microbial metabolism. Eur. J. Nutr. 51:899-907. http://dx.doi.org/10.1007/s00394 -012-0415-4.
44. Steubesand N, Kiehne K, Brunke G, Pahl R, Reiss K, Herzig KH, Schubert S, Schreiber S, Folsch UR, Rosenstiel P, Arlt A. 2009. The expression of the beta-defensins hBD-2 and hBD-3 is differentially regulated by NF-kappaB and MAPK/AP-1 pathways in an in vitro model of Candida esophagitis. BMC Immunol. 10:36. http://dx.doi.org/10.1186 /1471-2172-10-36.
45. Sorensen O, Arnljots K, Cowland JB, Bainton DF, Borregaard N. 1997. The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 90:2796-2803.
46. Rumio C, Besusso D, Palazzo M, Selleri S, Sfondrini L, Dubini F, Menard S, Balsari A. 2004. Degranulation of Paneth cells via Toll-like receptor 9. Am. J. Pathol. 165:373-381. http://dx.doi.org/10.1016/S0002 -9440(10)63304-4.
47. Brinkmann V, Zychlinsky A. 2007. Beneficial suicide: why neutrophils die to make NETs. Nat. Rev. Microbiol. 5:577-582. http://dx.doi.org/10. 1038/nrmicro1710.
48. Mantovani A, Cassatella MA, Costantini C, Jaillon S. 2011. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 11:519-531. http://dx.doi.org/10.1038/nri3024.
49. Stewart FA, Denekamp J, Randhawa VS. 1982. Skin sensitization by misonidazole: a demonstration of uniform mild hypoxia. Br. J. Cancer 45:869-877. http://dx.doi.org/10.1038/bjc.1982.139.
50. Peyssonnaux C, Boutin AT, Zinkernagel AS, Datta V, Nizet V, Johnson RS. 2008. Critical role of HIF-1alpha in keratinocyte defense against bacterial infection. J. Investig. Dermatol. 128:1964-1968. http://dx.doi.org /10.1038/jid.2008.27.
51. Kanda N, Kano R, Ishikawa T, Watanabe S. 2011. The antimycotic drugs itraconazole and terbinafine hydrochloride induce the production of human beta-defensin-3 in human keratinocytes. Immunobiology 216:497- 504. http://dx.doi.org/10.1016/j.imbio.2010.08.008.
52. Frick IM, Åkesson P, Rasmussen M, Schmidtchen A, Björck L. 2003. SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides. J. Biol. Chem. 278:16561-16566. http://dx.doi.org/10.1074 /jbc.M301995200.
53. Meiller TF, Hube B, Schild L, Shirtliff ME, Scheper MA, Winkler R, Ton A, Jabra-Rizk MA. 2009. A novel immune evasion strategy of Candida albicans: proteolytic cleavage of a salivary antimicrobial peptide. PLoS One 4:e5039. http://dx.doi.org/10.1371/journal.pone.0005039.
54. Swidergall M, Ernst AM, Ernst JF. 2013. Candida albicans mucin Msb2 is a broad-range protectant against antimicrobial peptides. Antimicrob. Agents Chemother. 57:3917-3922. http://dx.doi.org/10.1128/AAC.00862 -13.
55. Szafranski-Schneider E, Swidergall M, Cottier F, Tielker D, Roman E, Pla J, Ernst JF. 2012. Msb2 shedding protects Candida albicans against antimicrobial peptides. PLoS Pathog. 8:e1002501. http://dx.doi.org/10. 1371/journal.ppat.1002501.
56. Argimon S, Fanning S, Blankenship JR, Mitchell AP. 2011. Interaction between the Candida albicans high-osmolarity glycerol (HOG) pathway and the response to human beta-defensins 2 and 3. Eukaryot. Cell 10:272- 275. http://dx.doi.org/10.1128/EC.00133-10.
57. Jung SI, Finkel JS, Solis NV, Chaili S, Mitchell AP, Yeaman MR, Filler SG. 2013. Bcr1 functions downstream of Ssd1 to mediate antimicrobial peptide resistance in Candida albicans. Eukaryot. Cell 12:411-419. http: //dx.doi.org/10.1128/EC.00285-12.
58. Lis M, Liu TT, Barker KS, Rogers PD, Bobek LA. 2010. Antimicrobial peptide MUC7 12-mer activates the calcium/calcineurin pathway in Candida albicans. FEMS Yeast Res. 10:579-586.
59. Puri S, Kumar R, Chadha S, Tati S, Conti HR, Hube B, Cullen PJ, Edgerton M. 2012. Secreted aspartic protease cleavage of Candida albicans Msb2 activates Cek1 MAPK signaling affecting biofilm formation and oropharyngeal candidiasis. PLoS One 7:e46020. http://dx.doi.org/10. 1371/journal.pone.0046020. (Author Correction, 8:10.1371/annotation /13ef5e14-c192-4bb2-af91-886024500b4b, 2013. http://dx.doi.org/10. 1371/annotation/13ef5e14-c192-4bb2-af91-886024500b4b.)
60. Li R, Kumar R, Tati S, Puri S, Edgerton M. 2013. Candida albicans Flu1-mediated efflux of salivary histatin 5 reduces its cytosolic concentration and fungicidal activity. Antimicrob. Agents Chemother. 57:1832- 1839. http://dx.doi.org/10.1128/AAC.02295-12.
61. Vylkova S, Jang WS, Li W, Nayyar N, Edgerton M. 2007. Histatin 5 initiates osmotic stress response in Candida albicans via activation of the Hog1 mitogen-activated protein kinase pathway. Eukaryot. Cell 6:1876- 1888. http://dx.doi.org/10.1128/EC.00039-07.
62. Hayes BM, Bleackley MR, Wiltshire JL, Anderson MA, Traven A, van der Weerden NL. 2013. Identification and mechanism of action of the plant defensin NaD1 as a new member of the antifungal drug arsenal against Candida albicans. Antimicrob. Agents Chemother. 57:3667-3675. http://dx.doi.org/10.1128/AAC.00365-13.
63. Alonso-Monge R, Carvaihlo S, Nombela C, Rial E, Pla J. 2009. The Hog1 MAP kinase controls respiratory metabolism in the fungal pathogen Candida albicans. Microbiology 155:413-423. http://dx.doi.org/10.1099/mic. 0.023309-0.
64. Gank KD, Yeaman MR, Kojima S, Yount NY, Park H, Edwards JE, Jr, Filler SG, Fu Y. 2008. SSD1 is integral to host defense peptide resistance in Candida albicans. Eukaryot. Cell 7:1318-1327. http://dx.doi.org/10. 1128/EC.00402-07.
65. Bharucha N, Chabrier-Rosello Y, Xu T, Johnson C, Sobczynski S, Song Q, Dobry CJ, Eckwahl MJ, Anderson CP, Benjamin AJ, Kumar A, Krysan DJ. 2011. A large-scale complex haploinsufficiency-based genetic interaction screen in Candida albicans: analysis of the RAM network during morphogenesis. PLoS Genet. 7:e1002058. http://dx.doi.org/10.1371 /journal.pgen.1002058.
66. Cruz MC, Goldstein AL, Blankenship JR, Del Poeta M, Davis D, Cardenas ME, Perfect JR, McCusker JH, Heitman J. 2002. Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J. 21:546-559. http://dx.doi.org/10.1093/emboj/21.4.546.
67. Sanglard D, Ischer F, Marchetti O, Entenza J, Bille J. 2003. Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol. Microbiol. 48:959-976. http://dx.doi.org/10. 1046/j.1365-2958.2003.03495.x.
68. Lenardon MD, Lesiak I, Munro CA, Gow NA. 2009. Dissection of the Candida albicans class I chitin synthase promoters. Mol. Genet. Genomics 281:459-471. http://dx.doi.org/10.1007/s00438-009-0423-0.
69. Tanida T, Okamoto T, Ueta E, Yamamoto T, Osaki T. 2006. Antimicrobial peptides enhance the candidacidal activity of antifungal drugs by promoting the efflux of ATP from Candida cells. J. Antimicrob. Chemother. 57:94-103.
70. Walker LA, Munro CA, De Bruijn I, Lenardon MD, McKinnon A, Gow NAR. 2008. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog. 4:e1000040. http://dx.doi.org/10.1371 /journal.ppat.1000040.
71. Zasloff M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395. http://dx.doi.org/10.1038/415389a.
72. Moise PA, North D, Steenbergen JN, Sakoulas G. 2009. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect. Dis. 9:617-624. http://dx.doi. org/10.1016/S1473-3099(09)70200-2.
73. Akerey B, Le-Lay C, Fliss I, Subirade M, Rouabhia M. 2009. In vitro efficacy of nisin Z against Candida albicans adhesion and transition following contact with normal human gingival cells. J. Appl. Microbiol. 107: 1298-1307. http://dx.doi.org/10.1111/j.1365-2672.2009.04312.x.
74. Harriott MM, Noverr MC. 2009. Candida albicans and Staphylococcus aureus form polymicrobial biofilms: effects on antimicrobial resistance. Antimicrob. Agents Chemother. 53:3914-3922. http://dx.doi.org/10. 1128/AAC.00657-09.
75. Mallick EM, Bennett RJ. 2013. Sensing of the microbial neighborhood by Candida albicans. PLoS Pathog. 9:e1003661. http://dx.doi.org/10.1371 /journal.ppat.1003661.
76. Harriott MM, Noverr MC. 2010. Ability of Candida albicans mutants to induce Staphylococcus aureus vancomycin resistance during polymicrobial biofilm formation. Antimicrob. Agents Chemother. 54:3746-3755. http: //dx.doi.org/10.1128/AAC.00573-10.
77. Moudgal V, Sobel J. 2010. Antifungals to treat Candida albicans. Expert Opin. Pharmacother. 11:2037-2048. http://dx.doi.org/10.1517/14656566. 2010.493875.
78. Katiyar S, Pfaller M, Edlind T. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50:2892-2894. http://dx.doi.org/10.1128 /AAC.00349-06.
79. Sanglard D, Odds FC. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2:73-85. http://dx.doi.org/10.1016/S1473-3099(02)00181-0.
80. Velden WJ, van Iersel TM, Blijlevens NM, Donnelly JP. 2009. Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1- 11). BMC Med. 7:44. http://dx.doi.org/10.1186/1741-7015-7-44.
81. Tokle T, McClements DJ. 2011. Physicochemical properties of lactoferrin stabilized oil-in-water emulsions: effects of pH, salt and heating. Food Hydrocolloids 25:976-982. http://dx.doi.org/10.1016/j.foodhyd.2010.09. 012.
82. Venkatesh MP, Rong L. 2008. Human recombinant lactoferrin acts synergistically with antimicrobials commonly used in neonatal practice against coagulase-negative staphylococci and Candida albicans causing neonatal sepsis. J. Med. Microbiol. 57:1113-1121. http://dx.doi.org/10. 1099/jmm.0.2008/001263-0.
83. Tati S, Li R, Puri S, Kumar R, Davidow P, Edgerton M. 2014. Histatin 5-spermidine conjugates have enhanced fungicidal activity and efficacy as a topical therapeutic for oral candidiasis. Antimicrob. Agents Chemother. 58:756-766.
84. Zhang L, Falla TJ. 2010. Potential therapeutic application of host defense peptides. Methods Mol. Biol. 618:303-327. http://dx.doi.org/10.1007/978 -1-60761-594-1_19.
85. Thevissen K, Kristensen HH, Thomma BP, Cammue BP, Francois IE. 2007. Therapeutic potential of antifungal plant and insect defensins. Drug Discov. Today 12:966-971. http://dx.doi.org/10.1016/j.drudis.2007.07. 016.
86. Thevissen K, de Mello Tavares P, Xu D, Blankenship J, Vandenbosch D, Idkowiak-Baldys J, Govaert G, Bink A, Rozental S, de Groot PW, Davis TR, Kumamoto CA, Vargas G, Nimrichter L, Coenye T, Mitchell A, Roemer T, Hannun YA, Cammue BP. 2012. The plant defensin RsAFP2 induces cell wall stress, septin mislocalization and accumulation of ceramides in Candida albicans. Mol. Microbiol. 84:166-180. http://dx.doi. org/10.1111/j.1365-2958.2012.08017.x.
87. Maurya IK, Thota CK, Verma SD, Sharma J, Rawal MK, Ravikumar B, Sen S, Chauhan N, Lynn AM, Chauhan VS, Prasad R. 2013. Rationally designed transmembrane peptide mimics of the multidrug transporter protein Cdr1 act as antagonists to selectively block drug efflux and chemosensitize azole-resistant clinical isolates of Candida albicans. J. Biol. Chem. 288:16775-16787. http://dx.doi.org/10.1074/jbc.M113.467159.
88. Jang WS, Bajwa JS, Sun JN, Edgerton M. 2010. Salivary histatin 5 internalization by translocation, but not endocytosis, is required for fungicidal activity in Candida albicans. Mol. Microbiol. 77:354-370. http://dx. doi.org/10.1111/j.1365-2958.2010.07210.x.
89. Edgerton M, Koshlukova SE. 2000. Salivary histatin 5 and its similarities to the other antimicrobial proteins in human saliva. Adv. Dent. Res. 14: 16-21. http://dx.doi.org/10.1177/08959374000140010201.
90. Andres MT, Viejo-Diaz M, Fierro JF. 2008. Human lactoferrin induces apoptosis-like cell death in Candida albicans: critical role of K+-channelmediated K+ efflux. Antimicrob. Agents Chemother. 52:4081-4088. http://dx.doi.org/10.1128/AAC.01597-07.